NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) disclosed several significant corporate and regulatory developments on November 13, 2026.
Executive Share Acquisition
According to a Form 4 filing, Chief Executive Officer Amir Heshmatpour acquired 30,000 shares of the company’s common stock through an open-market transaction on November 13, 2026. This transaction increases Heshmatpour’s direct holdings to approximately 3.35 million shares. Additionally, a Form 8-K filing indicated that Heshmatpour had purchased an additional 80,000 shares during the current month. The company confirmed that no new shares were issued in connection with these executive purchases.
Regulatory and Clinical Developments
The company has secured a U.S. Food and Drug Administration (FDA) Type B End-of-Phase meeting. The purpose of this meeting is to discuss a potential accelerated approval pathway for NEO100, the company’s intranasal product.
This regulatory milestone follows recent Phase 2a study results, which demonstrated a progression-free survival rate exceeding the pre-defined benchmark. NeOnc Technologies Holdings intends to present this clinical data at the upcoming Society for Neuro-Oncology Annual Meeting.
Company Profile
NeOnc Technologies Holdings is a clinical-stage biopharmaceutical firm specializing in therapies for central nervous system cancers. As of the market close on November 12, 2026, the company’s shares were trading at 4.91 USD, with a market capitalization of 136,360,000 USD.




